Datapoint: AstraZeneca’s Saphnelo Cleared to Treat Lupus
August
3
The FDA on Monday approved AstraZeneca’s Saphnelo for the treatment of moderate to severe systemic lupus erythematosus (SLE), the most common form of the disease. The type I interferon receptor antagonist is the first approval for SLE since 2011, when GlaxoSmithKline’s Benlysta entered the market. While Saphnelo could pose a threat, Benlysta is highly advantaged in the SLE market basket. Its intravenous form holds covered or better status for 94% of all insured lives under the medical benefit vs. 65% of lives under the pharmacy benefit.
SOURCE: MMIT Analytics, as of 8/2/21
© 2025 MMIT
